Publicaciones en colaboración con investigadores/as de Instituto de Investigación Biomédica de Salamanca (29)

2024

  1. Platelet C3G: a key player in vesicle exocytosis, spreading and clot retraction

    Cellular and Molecular Life Sciences, Vol. 81, Núm. 1

2023

  1. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  2. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  3. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

2022

  1. C3G down-regulation enhances pro-migratory and stemness properties of oval cells by promoting an epithelial-mesenchymal-like process

    International journal of biological sciences, Vol. 18, Núm. 15, pp. 5873-5884

  2. Evolutionary Origins of Metabolic Reprogramming in Cancer

    International journal of molecular sciences, Vol. 23, Núm. 20

  3. New functions of C3G in platelet biology: Contribution to ischemia-induced angiogenesis, tumor metastasis and TPO clearance

    Frontiers in Cell and Developmental Biology, Vol. 10

  4. Pathophysiological Integration of Metabolic Reprogramming in Breast Cancer

    Cancers, Vol. 14, Núm. 2

  5. RICORS2040: The need for collaborative research in chronic kidney disease

    Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387

2021

  1. C3G downregulation induces the acquisition of a mesenchymal phenotype that enhances aggressiveness of glioblastoma cells

    Cell Death and Disease, Vol. 12, Núm. 4

  2. C3G protein, a new player in glioblastoma

    International Journal of Molecular Sciences, Vol. 22, Núm. 18

  3. Contribution of c3g and other gefs to liver cancer development and progression

    Hepatoma Research, Vol. 7

  4. The evolving landscape of chronic lymphocytic leukemia on diagnosis, prognosis and treatment

    Diagnostics, Vol. 11, Núm. 5

2020

  1. C3G contributes to platelet activation and aggregation by regulating major signaling pathways

    Signal Transduction and Targeted Therapy, Vol. 5, Núm. 1

  2. C3G is upregulated in hepatocarcinoma, contributing to tumor growth and progression and to HGF/MET pathway activation

    Cancers, Vol. 12, Núm. 8, pp. 1-22

  3. Stromal SNAI2 is required for ERBB2 breast cancer progression

    Cancer Research, Vol. 80, Núm. 23, pp. 5216-5230

2018

  1. C3G, through its GEF activity, induces megakaryocytic differentiation and proplatelet formation

    Cell Communication and Signaling, Vol. 16, Núm. 1

  2. Supplementary data for the biological age linked to oxidative stress modifies breast cancer aggressiveness

    Data in Brief

  3. The biological age linked to oxidative stress modifies breast cancer aggressiveness

    Free Radical Biology and Medicine, Vol. 120, pp. 133-146

2017

  1. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts

    Leukemia Research, Vol. 56, pp. 82-87